NFKB1 and systemic lupus erythematosus: Animal experiments suggest that 1,25-dihydroxyvitamin D3 can significantly inhibit the NF-κB and MAPK signaling pathways to improve lupus activity, providing a potential target for the treatment of LN (Li et al., 2022).